Physician profile
Meena Gulati
NPI 1194794065
$2,289.43
in general payments reported to CMS, 2019-2025
10 companies · $779 in 2025
The $779 reported for 2025 was more than what 80% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $669 · 2024: $841 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $499.94 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $447.58 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $243.78 | 2023-2025 | |
| Tris Pharma INC | $235.56 | 2025 | Quillivant, Dyanavel Xr, Quillichew Er |
| Otsuka America Pharmaceutical, INC. | $218.51 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $212.43 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $138.36 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $105.28 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $98.34 | 2023 | Quviviq |
| Corium, LLC | $89.65 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.